SCHEMBL21687984

SCHEMBL21687984

N#Cc1ccc(-c2ccccc2[Si](c2ccccc2)(c2ccccc2)c2ccccc2)cc1-n1c2ccccc2c2ccccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.34
CYP11B1 P15538 1/20 0.34
AR P10275 5/20 0.33
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TRPA1 O75762 1/20 0.33
LMNA P02545 2/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
PGR P06401 2/20 0.32
IMPDH2 P12268 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21688105 0.93 PTGER4 (0.33) CYP11B2CYP11B1NR3C1
SCHEMBL21687609 0.92 ALDH1A1 (0.34) CYP11B2CYP11B1ARALDH1A1SMN1; SMN2
SCHEMBL21687775 0.91 SMN1; SMN2 (0.34) CYP11B2CYP11B1ARALDH1A1SMN1; SMN2
SCHEMBL21688056 0.89 CYP11B1 (0.32) CYP11B2CYP11B1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21687481 0.89 NR3C1 (0.31) CYP11B2CYP11B1ARALDH1A1SMN1; SMN2
SCHEMBL21688185 0.89 CYP11B1 (0.32) CYP11B2CYP11B1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21687628 0.88 CYP11B2 (0.34) CYP11B2CYP11B1ARALDH1A1SMN1; SMN2
SCHEMBL21687739 0.88 KDM4E (0.35) CYP11B2CYP11B1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21688108 0.87 KDM4E (0.34) CYP11B2CYP11B1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL21687772 0.85 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2KDM4EATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2021-12-14 US disclosed
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND SAMSUNG ELECTRONICS CO., LTD. (KR) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200044168-A1 CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND CRY1, CCNL2, CCNE2 CYP11B2 1646/4885CYP11B1 1222/4885AR 1928/4885
US-11201300-B2 Condensed cyclic compound and organic light-emitting device including condensed cyclic compound CRY1, CCNL2, CCNE2 CYP11B2 1646/4885CYP11B1 1222/4885AR 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.